204 related articles for article (PubMed ID: 31318041)
1. Tofacitinib for the treatment of recalcitrant palmoplantar pustulosis: A case report.
Haynes D; Topham C; Hagstrom E; Greiling T
Australas J Dermatol; 2020 Feb; 61(1):e108-e110. PubMed ID: 31318041
[No Abstract] [Full Text] [Related]
2. Successful treatment of palmoplantar pustulosis with rheumatoid arthritis, with tofacitinib: Impact of this JAK inhibitor on T-cell differentiation.
Koga T; Sato T; Umeda M; Fukui S; Horai Y; Kawashiri SY; Iwamoto N; Ichinose K; Nakamura H; Kawakami A
Clin Immunol; 2016 Dec; 173():147-148. PubMed ID: 27720846
[No Abstract] [Full Text] [Related]
3. XELJANZ (Tofacitinib) for Chronic Plaque Psoriasis.
Gupta AK; Daigle D; Abramovits W; Vincent KD
Skinmed; 2015; 13(3):227-9. PubMed ID: 26380510
[No Abstract] [Full Text] [Related]
4. Tofacitinib and other kinase inhibitors in the treatment of psoriasis.
Ortiz-Ibáñez K; Alsina MM; Muñoz-Santos C
Actas Dermosifiliogr; 2013 May; 104(4):304-10. PubMed ID: 23583515
[TBL] [Abstract][Full Text] [Related]
5. Tofacitinib in the Treatment of Rheumatoid Arthritis and Chronic Plaque Psoriasis.
Gupta AK; Cernea M; Lynde CW
Skin Therapy Lett; 2017 Mar; 22(2):1-7. PubMed ID: 28329404
[TBL] [Abstract][Full Text] [Related]
6. Killing two birds with one stone: oral tofacitinib reverses alopecia universalis in a patient with plaque psoriasis.
Craiglow BG; King BA
J Invest Dermatol; 2014 Dec; 134(12):2988-2990. PubMed ID: 24940651
[No Abstract] [Full Text] [Related]
7. Tofacitinib for the treatment of moderate-to-severe psoriasis.
Chiricozzi A; Faleri S; Saraceno R; Bianchi L; Buonomo O; Chimenti S; Chimenti MS
Expert Rev Clin Immunol; 2015 Apr; 11(4):443-55. PubMed ID: 25666451
[TBL] [Abstract][Full Text] [Related]
8. Tofacitinib in psoriatic arthritis.
Wang TS; Tsai TF
Immunotherapy; 2017 Nov; 9(14):1153-1163. PubMed ID: 28967798
[TBL] [Abstract][Full Text] [Related]
9. Tofacitinib (CP-690,550), an oral Janus kinase inhibitor, improves patient-reported outcomes in a phase 2b, randomized, double-blind, placebo-controlled study in patients with moderate-to-severe psoriasis.
Mamolo C; Harness J; Tan H; Menter A
J Eur Acad Dermatol Venereol; 2014 Feb; 28(2):192-203. PubMed ID: 23294276
[TBL] [Abstract][Full Text] [Related]
10. Do we need more psoriasis therapies?
Lebwohl M
Lancet; 2015 Aug; 386(9993):512-4. PubMed ID: 26051367
[No Abstract] [Full Text] [Related]
11. Tofacitinib for the treatment of psoriasis.
Galluzzo M; D'Adamio S; Servoli S; Bianchi L; Chimenti S; Talamonti M
Expert Opin Pharmacother; 2016 Jul; 17(10):1421-33. PubMed ID: 27267933
[TBL] [Abstract][Full Text] [Related]
12. Tofacitinib attenuates pathologic immune pathways in patients with psoriasis: A randomized phase 2 study.
Krueger J; Clark JD; Suárez-Fariñas M; Fuentes-Duculan J; Cueto I; Wang CQ; Tan H; Wolk R; Rottinghaus ST; Whitley MZ; Valdez H; von Schack D; O'Neil SP; Reddy PS; Tatulych S;
J Allergy Clin Immunol; 2016 Apr; 137(4):1079-1090. PubMed ID: 27059729
[TBL] [Abstract][Full Text] [Related]
13. Improvement of lymphangioleiomyomatosis following successful tofacitinib treatment for refractory synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome.
Liu S; Li C; Tang MW; Xu WS; Chen KQ; Sui X; Tian XL; Xu KF
Chin Med J (Engl); 2019 Oct; 132(19):2378-2379. PubMed ID: 31503058
[No Abstract] [Full Text] [Related]
14. Efficacy of tofacitinib for the treatment of nail psoriasis: Two 52-week, randomized, controlled phase 3 studies in patients with moderate-to-severe plaque psoriasis.
Merola JF; Elewski B; Tatulych S; Lan S; Tallman A; Kaur M
J Am Acad Dermatol; 2017 Jul; 77(1):79-87.e1. PubMed ID: 28396102
[TBL] [Abstract][Full Text] [Related]
15. Tofacitinib for the treatment of moderate to severe chronic plaque psoriasis in Japanese patients: Subgroup analyses from a randomized, placebo-controlled phase 3 trial.
Abe M; Nishigori C; Torii H; Ihn H; Ito K; Nagaoka M; Isogawa N; Kawaguchi I; Tomochika Y; Kobayashi M; Tallman AM; Papp KA
J Dermatol; 2017 Nov; 44(11):1228-1237. PubMed ID: 28714180
[TBL] [Abstract][Full Text] [Related]
16. Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial.
Bachelez H; van de Kerkhof PC; Strohal R; Kubanov A; Valenzuela F; Lee JH; Yakusevich V; Chimenti S; Papacharalambous J; Proulx J; Gupta P; Tan H; Tawadrous M; Valdez H; Wolk R;
Lancet; 2015 Aug; 386(9993):552-61. PubMed ID: 26051365
[TBL] [Abstract][Full Text] [Related]
17. Tofacitinib improves pruritus and health-related quality of life up to 52 weeks: Results from 2 randomized phase III trials in patients with moderate to severe plaque psoriasis.
Feldman SR; Thaçi D; Gooderham M; Augustin M; de la Cruz C; Mallbris L; Buonanno M; Tatulych S; Kaur M; Lan S; Valdez H; Mamolo C
J Am Acad Dermatol; 2016 Dec; 75(6):1162-1170.e3. PubMed ID: 27692733
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of tofacitinib for the treatment of chronic plaque psoriasis: a systematic review and meta-analysis.
Tian F; Chen Z; Xu T
J Int Med Res; 2019 Jun; 47(6):2342-2350. PubMed ID: 31096817
[TBL] [Abstract][Full Text] [Related]
19. Reduction of Inflammatory and Cardiovascular Proteins in the Blood of Patients with Psoriasis: Differential Responses between Tofacitinib and Etanercept after 4 Weeks of Treatment.
Kim J; Tomalin L; Lee J; Fitz LJ; Berstein G; Correa-da Rosa J; Garcet S; Lowes MA; Valdez H; Wolk R; Suarez-Farinas M; Krueger JG
J Invest Dermatol; 2018 Feb; 138(2):273-281. PubMed ID: 28927890
[TBL] [Abstract][Full Text] [Related]
20. Emerging Oral Immunomodulators for the Treatment of Psoriasis: A Review of Phase III Clinical Trials for Apremilast and Tofacitinib.
McAndrew R; Levin E; Koo J
J Drugs Dermatol; 2015 Aug; 14(8):786-92. PubMed ID: 26267722
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
